<DOC>
	<DOCNO>NCT00383864</DOCNO>
	<brief_summary>The purpose study evaluate efficacy ( safety ) antiviral therapy patient chronic hepatitis C liver transplantation . The approved drug treatment hepatitis C pegylated interferon ribavirin .</brief_summary>
	<brief_title>Pegylated Interferon Ribavirin Hepatitis C Virus Infection After Liver Transplantation .</brief_title>
	<detailed_description>Hepatitis C recurrence liver transplantation remain main cause graft loss liver transplantation . Several strategy use prevent treat hepatitis C set liver transplantation . There controlled study evaluate efficacy safety antiviral treatment ( use pegylated interferon ribavirin ) liver transplant recipient . The main endpoint study : 1 ) histological outcome ( effect antiviral treatment disease progression , i.e . liver fibrosis ) . The secondary endpoint 1 ) Sustained virological response ( persistent HCV-RNA clearance ) 2 ) Safety pegylated interferon ribavirin</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Chronic hepatitis C define liver biopsy presence HCVRNA More 6 month liver transplantation Written inform consent Severe hepatitis C recurrence ( F3F4 fibrosis stage , cholestatic hepatitis ) Double liverkidney transplantation Leucopenia ( 2000 ) thrombocytopenia ( 40.000 ) Anemia ( Hemoglobin low 10 g/dL ) Renal failure ( creatinine &gt; 2 mg/dL ) Autoimmune disease All contraindication interferon ribavirin therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>liver fibrosis</keyword>
	<keyword>portal pressure</keyword>
	<keyword>antiviral therapy</keyword>
</DOC>